Armata Pharmaceuticals Inc (ARMP)

Healthcare Biotechnology

5.10 $

Closing price · As of: 20. Jul 2026

Add to watchlist

Appears in These Scanners

This stock currently matches 13 of our scanner strategies — each hit links to the scanner.

Breakout & Setup

Gap-Up (≥3%) Pradeep Bonde: 4% Breakout Bullish Volume Surge

Momentum & Trend

Gary Antonacci: Dual Momentum (Stock Adaptation) High ADR (≥5%) Power Trend RS Leader (≥90) Richard Moglen: Gaps and Strong Moves Stan Weinstein: Stage 1

Risk & Weakness

Altman Z: Distress Zone Below the 50- & 200-SMA Going Concern (Distress Proxy) Insolvency Radar: Cash Running Low

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap

0.2Mrd. $

Shares Outstanding

37Mio.

Float

31.5%

Beta

1.3

Performance

Perf. 1M

-20.40%

Perf. 3M

-22.80%

Perf. 6M

0.80%

YTD Performance (%)

11.60%

52-Week-High Distance

-60.2%

Valuation

P/E

–

Forward P/E

0.0

PEG

–

P/B

–

P/S

45.5

EV/EBITDA

-3.5

Price/FCF

–

Profitability

Gross Margin

-215.2%

EBIT Margin

–

Net Margin

0.0%

Return on Equity

-3,439.4%

Return on Assets

-25.3%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

–

warning zone

Altman Z

-52.15

Piotroski

4 von 9

Growth

Sales Growth Last Quarter

60.70%

EPS Growth Last Quarter

0.00%

Sales Growth (Year)

-5.22%

Forward Sales Growth

25.00%

Forward EPS Growth

–

Quality & Screener

Stage

Top 10%

RS Rating

EPS Rating

Piotroski

4 von 9

Fundamental Rating

D (-42 von 100)

warning zone

Altman Z

-52.15

AI Rating

Neutral

Geprüft am 10.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 25.03.2026) und den jüngsten Quartalsbericht (10-Q) zum 31.03.2026 (eingereicht 13.05.2026): In den ausgewerteten SEC-Filings von Armata Pharmaceuticals findet sich kein wesentlicher KI-Bezug. Armata ist ein klinisches Biotech-Unternehmen, das Bakteriophagen-Therapien gegen antibiotika-resistente Bakterien entwickelt (Leitkandidaten AP-PA02 und AP-SA02); künstliche Intelligenz ist weder Umsatzquelle noch als operatives Werkzeug (z. B. KI-gestützte Wirkstoffsuche) beschrieben. Die einzigen Erwähnungen sind generische Boilerplate: eine Aufzählung möglicher Zukunftsrisiken in den Forward-Looking-Statements des 10-K („the effects of artificial intelligence on our business and the industry as a whole“) sowie ein allgemeiner Risikofaktor, dass der breitere Einsatz von KI durch die Firma, Dritte und Wettbewerber neue operative Risiken schaffen könne. Nach der Vorrang-Regel begründet solche branchenweite Boilerplate weder „bedroht“ (kein konkretes KI-Geschäftsrisiko fürs eigene Phagen-Modell) noch „nutzt“ oder „verkauft“ — Einstufung damit „neutral“.

View the full file — quotes, sources, reviewed filings

Filings Reviewed: 10-K 2026-03-25 · 10-Q 2026-05-13

Rated on July 10, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Sales Per Quarter ($M)

Earnings Per Share Per Quarter ($)

Net Margin Per Quarter (%)

Operating Cash Flow Per Quarter ($M)

Free Cash Flow Per Quarter ($M)

Sales Growth vs. Year-Ago Quarter (%)

EPS Growth vs. Year-Ago Quarter (%)

Price Change in Quarter (%)

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	0.07	–	1	-19.20	210.50	-8	-8
2025: Q1	-0.18	–	1	-49.20	-1,330.10	-8	-8
2025: Q2	-0.44	-281.30	2	–	-751.30	-7	-7
2025: Q3	-0.73	–	1	-61.00	-2,301.60	-4	-5
2025: Q4	-3.39	-4,880.70	1	-12.10	-11,456.00	-7	-7
2026: Q1	-3.14	–	1	60.70	-14,619.30	-6	-6

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Armata Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Entwicklung zielgerichteter Bakteriophagen-Therapeutika gegen antibiotikaresistente Infektionen weltweit konzentriert.

Employees	61
Headquarters	Los Angeles, CA
Website	armatapharma.com
IPO Date	9. Mar 2011
Next Earnings	11. Aug 2026

Management

Management
Name	Title	Birth Year
Deborah L. Birx M.D.	CEO & Director	1957
David D. House	Senior VP of Finance & Principal Financial Officer	1984
Pierre Kyme Ph.D.	Chief Business Officer	1978
Peter Hubbard	Vice President of Operations	–
Bani Tchekanova Ph.D.	Head of Regulatory Strategy & Operations	–

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.